Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIII 890 CL in healthy volunteers
NCT02269215Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2000
- Primary completion
- Sep 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in ischemic stroke, epilepsy and pain comparing BIII 890 CL with Placebo (2 arms). Primary endpoints: Number of patients with clinically relevant changes in vital signs at 8 days, Number of subjects with clinically relevant changes in 12-lead ECG at 8 days and 2 more. Started Jan 2000; status: completed.
02
Drugs
crobenetine
03
Conditions
ischemic strokeepilepsypain
Beyond the preview
Go deeper on NCT02269215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269215.